摘要
Translational medicine has newly emerged to bridge the gap between bench-related basic science research and bedside clinical practice.From early diagnosis to late-stage disease treatment,translational medicine has transformed the clinical practice by making personalized medicine possible.Attributing to the progress in translational medical research,cancer therapy has evolved from non-specific cytotoxic drugs against both tumor and normal proliferating cells to more specific small molecule chemical and immunotherapy approaches.Small molecular agents are directed at unique pathogenesis of cancer cells,whereas immunotherapeutic agents target the cancer immune response.Both approaches aim to produce less toxicity with high effectiveness.Therapeutic regimens with these agents in biomarker-classified sensitive populations promises a personalized approach in modern oncology.
